Destiny Pharma PLC (AIM:DEST)'s (AIM:DEST) Neil Clark joins Proactive London's Katie Pilbeam to discuss the latest data from their recent Phase 2b clinical trial of its XF-73 nasal gel.
The additional data showed that cardiac surgery patients receiving XF-73 nasal gel exhibited a valuable, sustained nasal reduction of Staphylococcus aureus bacteria after wound closure.
Clark says this update demonstrates that XF-73 nasal gel has the potential to keep patients at a significantly low S. aureus nasal burden during the period of highest infection risk which runs from 1 hour prior to incision, during surgery itself, to the start of wound healing and out to at least 6 days post-surgery.